One CRISPR Shot Could Lower Bad Cholesterol for Years Without Permanent DNA Changes
Scribe Therapeutics wins approval to test a single-dose CRISPR therapy that silences the PCSK9 gene to durably cut LDL cholesterol.
Summary
A California biotech called Scribe Therapeutics has received regulatory clearance in Australia to begin the first human trial of STX-1150, a CRISPR-based therapy designed to lower LDL cholesterol long-term with just one dose. Rather than permanently rewriting DNA, it uses epigenetic silencing to suppress the PCSK9 gene in the liver — the same gene that, when naturally underactive, gives some people lifelong protection against heart disease. This approach could eventually replace decades of daily statins or repeat injections for high-risk patients. Cardiovascular disease kills more people globally than any other condition, and poor medication adherence is a major reason LDL targets go unmet. A durable, one-time treatment could close that gap significantly.
Detailed Summary
Cardiovascular disease remains the leading cause of death worldwide, and elevated LDL cholesterol is one of its most controllable risk factors. Yet daily statins and repeat PCSK9 inhibitor injections fail many patients in real-world settings due to side effects, adherence fatigue, and delayed treatment. Scribe Therapeutics is now testing whether a single CRISPR-based dose can deliver lasting cholesterol protection — a shift that could redefine preventive cardiology.
Australia's Therapeutic Goods Administration has cleared Scribe to begin the first human trial of STX-1150. The therapy targets PCSK9, a liver gene that regulates cholesterol metabolism and is among the most clinically validated targets in cardiovascular medicine. People born with naturally low PCSK9 activity have significantly lower LDL levels and far fewer heart attacks across their lifetimes. STX-1150 aims to recreate that protective biology therapeutically.
Critically, STX-1150 does not permanently rewrite DNA. Instead, it uses what Scribe calls epigenetic silencing through its ELXR platform — suppressing PCSK9 gene activity without altering the underlying genetic sequence. The company says this design offers long-lasting effects while preserving reversibility, potentially avoiding some of the ethical and regulatory concerns associated with permanent gene editing.
For longevity-focused readers, the implications extend well beyond cholesterol. This represents a broader shift in medicine: intervening earlier with durable therapies rather than managing chronic risk indefinitely. If STX-1150 works as intended, it could offer decades of cardiovascular protection from a single clinical visit.
Important caveats apply. This is a Phase 1 trial, meaning the primary goal is safety and dosing — efficacy data in humans does not yet exist. Long-term durability of epigenetic silencing in humans is unproven. Regulatory approval in multiple markets, manufacturing scale, and cost will all determine real-world accessibility. Results are likely years away from clinical translation.
Key Findings
- Single-dose STX-1150 aims to durably lower LDL cholesterol by silencing the PCSK9 gene epigenetically, not through permanent DNA editing.
- Australia's TGA has cleared the first human trial, marking CRISPR's entry into clinical cardiovascular prevention.
- PCSK9 is one of medicine's most validated cholesterol targets; people with naturally low PCSK9 have lifelong reduced heart disease risk.
- Epigenetic silencing preserves reversibility, potentially reducing ethical concerns versus permanent gene editing approaches.
- Poor long-term adherence to statins and injections is a major unmet need this one-time therapy could address.
Methodology
This is a news report from Longevity.Technology summarizing a clinical trial clearance announcement by Scribe Therapeutics. Evidence is based on company press statements and regulatory approval; no peer-reviewed trial data is yet available. Source credibility is moderate — Longevity.Technology is a specialist industry publication with generally reliable reporting on biotech developments.
Study Limitations
No human efficacy or safety data exists yet; Phase 1 trials focus on dosing and tolerability, not therapeutic outcomes. Long-term durability of epigenetic silencing in humans is entirely unproven. Readers should consult primary trial registries and peer-reviewed publications as data emerge rather than relying solely on company announcements.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.